ISEMBYLD for the Treatment of Spinal Muscular Atrophy, US
ISEMBYLD™ (apitegromab-mstn) is the first approved treatment for spinal muscular atrophy (SMA) to directly address muscle loss. It is designed to …
Projects
-
-
DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma, US
Danyelza® (naxitamab-gqgk) is a humanised immunotherapy indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of high-risk neuroblastoma …
-
Iqirvo for the Treatment of Primary Biliary Cholangitis, US
Iqirvo® (elafibranor) is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in …
-
Rasonque (daraxonrasib) for the treatment of metastatic PDAC, US
Rasonque™ (daraxonrasib) is indicated for the treatment of adult patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone at …
-
Apretude (cabotegravir) for the Treatment of HIV-1 Pre-Exposure Prevention (PrEP), US
Apretude (cabotegravir) is the first and only injectable long-acting pre-exposure prevention (PrEP) treatment to minimise the risk of sexually acquired …
-
ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive advanced gastric cancer
Enhertu® (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate indicated for the treatment of various types of cancer including gastric, breast and non-small …
-
ZENBEXUS (iberdomide) for the Treatment of Multiple Myeloma, US
ZENBEXUS™ (iberdomide), used in combination with daratumumab and hyaluronidase-fihj plus dexamethasone (ZDd), is indicated for the treatment of adult patients …
-
XOLREMDI (mavorixafor) for the Treatment of WHIM Syndrome, US
XOLREMDI™ (mavorixafor) is a first-in-class, oral therapy indicated for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a …
-
REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Breast Cancer, US
REVTORPYK (gedatolisib) is indicated for use in combination with fulvestrant, with or without palbociclib, for adult patients with hormone receptor …
-
Truqap (capivasertib) for the Treatment of Breast Cancer, US
Truqap® (capivasertib), in combination with Faslodex® (fulvestrant), is a novel therapeutic option for the treatment of hormone receptor (HR)-positive, HER2-negative …
-
XOCOVA (ensitrelvir) for the treatment of PEP of Covid-19, Japan
XOCOVA® (ensitrelvir) is authorised for the treatment of post-exposure prophylaxis (PEP) of coronavirus disease 2019 (Covid‑19) in adults and adolescents …
-
SPINRAZA for the Treatment of Spinal Muscular Atrophy, US
SPINRAZA (nusinersen) is indicated for the treatment of spinal muscular atrophy (SMA) in paediatric and adult patients. It was originally developed …
-
ELAHERE for the Treatment of Ovarian Cancer, US
ELAHERE® (mirvetuximab soravtansine) is a novel antibody-drug conjugate (ADC) indicated for the treatment of adult patients with folate receptor alpha …
-
Idvynso (doravirine/islatravir) for the Treatment of HIV-1 Infection, US
Idvynso™ (doravirine/islatravir) is a two‑drug, single‑tablet regimen containing doravirine and islatravir, authorised for the treatment of human immunodeficiency virus (HIV)‑1 …
-
Tezspire (tezepelumab-ekko) for the Treatment of Severe Asthma, US
Tezspire (tezepelumab-ekko) is a first-in-class human monoclonal antibody indicated for add-on maintenance treatment of severe asthma in adults and children …
